**Table 1 :** Patients’ characteristics

|  |  |
| --- | --- |
|  | Patient Population (n) |
| Age (median) | 56 (25-81) |
| Gender | Females(n):57/ Males (n):98 |
| MM  Subgroup | Heavy Chain (n): 116  Light Chain (n): 32  Non-secretory (n): 3  Not evaluated (n):4 |
| ISS | ISS I(n): 40  ISS II(n): 49  ISS III(n): 41  Not evaluated (n): 25 |
| R-ISS | R-ISS I (n): 21  R-ISS II (n): 60  R-ISS III (n): 11  Not evaluated (n): 63 |
| Durie Salmon | DS1(n): 5  DS2(n):16  DS3(n):129  Not evaluated (n): 5 |
| Pre-transplantation response | CR(n) : 58  VGPR(n): 39  PR(n): 41  Stable(n): 10  Refractory(n):3  Not evaluated (n): 4 |
| Chemotherapy line(s) | 1 line (n): 50  2 lines (n): 90  3 lines (n): 9  4 line (n): 2  Not evaluated (n):4 |
| Melphalan dose | 140mg/m2(n): 14  200mg/m2(n): 141 |
| Renal failure  (GFR<50 ml/min) | Present(n): 7  None(n): 148 |
| Radiotherapy | Applied(n) : 21  Not-applied(n):134 |
| Infused CD34+ cell (median) | 4.62 x106 /kg (2.4-13.4) |

*ISS: international staging system, R-ISS: revised-international staging system, CR: complete response, VGPR: very good partial response, PR: partial response, GFR: glomerular filtration rate,*

**Table 2:** The factors impacting OS

|  |  |  |
| --- | --- | --- |
|  | **PFS** | **OS** |
| **Gender** | 0.873 | 0.775 |
| **MM subtype** | 0.229 | 0.215 |
| **ISS** | 0.522 | 0.560 |
| **R-ISS** | 0.339 | 0.033\* |
| **Durie Salmon stage** | 0.824 | 0.973 |
| **Chemoterapy line(s) received** | 0.252 | 0.707 |
| **Melphalan dose** | 0.607 | 0.795 |
| **Pre-transplantation response** | 0.066 | 0.846 |

*PFS: progression-free survival, OS: overall survival, ISS: international staging system, R-ISS: revised-international staging system*